ASCO GU 2023

ASCO GU 2023
February 16-18, 2023
Moscone Center, San Francisco, California

American Society of Clinical Oncology Genitourinary Cancers Symposium.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (5)

    TROPHY-U-01 Cohort 2, a Phase 2 Study of Sacituzumab Govitecan in Platinum-Ineligible Patients With Metastatic Urothelial Cancer who Progressed After Prior Checkpoint Inhibitor Therapy

    • Author(s): Petrylak, Daniel
    • trodelvy
    • Oncology

    Primary Analysis of TROPHY-U-01 Cohort 3, a Phase 2 Study of Sacituzumab Govitecan in Combination With Pembrolizumab in Patients With Metastatic Urothelial Cancer Who Progressed After Platinum-Based Therapy

    • Author(s): Grivas, Petros
    • trodelvy
    • Oncology

    TROPHY-U-01 Cohort 5: Evaluation of Maintenance Sacituzumab Govitecan Plus Zimberelimab, Zimberelimab, or Avelumab in Cisplatin-Eligible Patients With Unresectable or Metastatic Urothelial Cancer

    • Author(s): Powles, Thomas
    • trodelvy
    • Oncology

    Updated Outcomes in TROPHY-U-01 Cohort 1, a Phase 2 Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Cancer Who Progressed After Platinum-Based Chemotherapy and a Checkpoint Inhibitor

    • Author(s): Tagawa, Scott
    • trodelvy
    • Oncology

    TROPHY-U-01 Cohort 6: Sacituzumab Govitecan, Sacituzumab Govitecan Plus Zimberelimab, Sacituzumab Govitecan Plus Zimberelimab Plus Domvanalimab, or Carboplatin + Gemcitabine in Cisplatin-Ineligible Patients With Treatment-Naïve Metastatic

    • Author(s): Duran, Ignacio
    • trodelvy
    • Oncology